Manufactures medical marijuana clones. Distributes clones under the Clones By Drones brand. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 131% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.3× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 5 years, sales grew about 131% a year on average.
Sales run at $2.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 5 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $297K against $2.3M in annual sales.
The stock sits at $0.0014. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.